House Oversight Committee report combats industry claims that lower drug prices would stifle innovation.
prescription drugs
Posted inDay One Agenda
Unleash the Existing Anti-Monopoly Arsenal
Corporate power can be neutralized if federal agencies simply used the prodigious authority they’ve been granted.
Posted inHealth and Social Policy
The Post-COVID Health Care System Is Out of Control
After gouging Americans for record pandemic profits, the health care industry sets its sights on even more.
Posted inHealth and Social Policy
The Dangers of Ducking the Health Care Fight
Each day that policymakers decide not to take on health interests is a day that those interests get bigger and tougher to dislodge.
Posted inTAP
Paying for Biden’s Program—Time to Get More Creative
Today on TAP: Alternatives to raising taxes
Posted inFirst 100
First 100: The Day One Agenda Has Stalled Out
Biden has failed to act and is even allowing constraints on executive action to move forward. Plus: the SALT battle continues.
Posted inPolitics
The Progressive Policies Moderates Hate Provide the Cost Savings Moderates Claim to Want
If moderate Democrats are serious about their demands to offset the cost of Biden’s infrastructure plan, they can start by saving billions through prescription drug price reform.
Posted inMoney, Politics, and Power
Astroturf Campaign Attacks Discount Drug Program for the Poor
An anti–government waste group is helping its Big Pharma funder oppose a discount drug program that doesn’t cost the government a penny.
Posted inPolitics
Democrats Should Be Louder About Trumpian Con Artistry
The ridiculous health care pronouncements last week serve as an example.